Comparing cytomegalovirus prophylaxis in renal transplantation: Single center experience

Transplant Infectious Disease

Volumn 7, Issue 2, 2005, Pages 63-67

  Varga, Marina ^a   Remport, A ^a   Hidvegi M ^a   Peter A ^a   Kobori L ^a   Telkes, G ^a   Fazakas, J ^a   Gerlei, Z ^a   Sarvary E ^a   Sulyok, B ^a   Jaray J ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cytomegalovirus (CMV); Ganciclovir; Hyperimmune gammaglobulin; Prophylaxis; Seronegative patients; Seropositive patients

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; AGED; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 25144518595     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2005.00094.x     Document Type: Review

References (17)

1. GINEVRI F, LOSURDO G, FONTANA I, et al. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients. Transpl Int 1998: 11 (Suppl 1): S130-S134.
2. VARGA M, GÖRÖG D, KÁRI D, et al. Viral screening of organ donors and human cytomegalovirus seroprevalence in the Hungarian population. Orv Hetil 2001: 142: 2631-2633 (in Hungarian).
3. FREEMAN RB, PAYA C, PESCOVITZ MD, et al. Risk factors for cytomegalovirus viraemia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004: 78: 1765-1773.
4. GUTIÉRREZ CA, CHAPARRO C, KRAJDEN M, WINTON T, KESTEN S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998: 113: 924-932.
5. REISCHIG T, OPATRNY K, BOUDA M, TRESKA V, JINDRA P, SVECOVA M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl Int 2002: 15: 615-622.
6. MÜLLEN GM, SILVER MA, MALINOWSKA K, et al. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients. Transplant Proc 1998: 30: 4110-4112.
7. LOWANCE D, NEUMAYER HH, LEGENDRE CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999: 340: 1462-1470.
8. ARBO MDJ, SNYDMAN DR, WONG JB, GOLDBERG HS, SCHMID CH, PAUKER SG. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis. Clin Transpl 2000: 14: 19-27.
9. GUIRADO L, HERREROS MA, MUNOZ JM, et al. Use of cytomegalovirus antigenemia as a marker for preemptive treatment. Transplant Proc 2002: 34: 67-68.
10. REISCHIG T, JINDRA P, MARES J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005: 79: 317-324.
11. MURRAY BM, AMSTERDAM D, GRAY V, MYERS J, GERBASI J, VENUTO R. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 1997: 8: 1448-1457.
12. LJUNGMAN P, GRIFFITHS P, PAYA C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002: 34: 1094-1097.
13. RACUSEN LC, SOLEZ K, COLVIN RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713-723.
14. PAYA CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999: 1 (Suppl 1): 8-12.
15. VILLACIAN JS, PAYA CV. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis 1999: 1: 50-64.
16. HUMAR A, PAYA C, PESCOVITZ MD, et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D +/R - solid organ transplant recipients. Am J Transplant 2004: 4: 644-649.
17. SAGEDAL S, NORDAL KP, HARTMANN A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002: 2: 850-856.